



**Patent Office
Canberra**

I, JONNE YABSLEY, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PQ 0701 for a patent by THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH filed on 01 June 1999.

WITNESS my hand this
Tenth day of April 2001

A handwritten signature in cursive script that reads "J R Yabsley".

JONNE YABSLEY
TEAM LEADER EXAMINATION
SUPPORT AND SALES

THIS PAGE BLANK (USPTO)

The Walter and Eliza Hall Institute of Medical Research

A U S T R A L I A

Patents Act 1990

PROVISIONAL SPECIFICATION

for the invention entitled:

"A method of modulating cell survival and reagents useful for same-III"

The invention is described in the following statement:

- 1A -

A METHOD OF MODULATING CELL SURVIVAL AND REAGENTS USEFUL FOR SAME-III

5 FIELD OF THE INVENTION

The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neuronal cells as well as facilitating cell death such as the death of targeted cancer
10 cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75^{NTR}) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75^{NTR} which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides
15 and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75^{NTR}.

BACKGROUND OF THE INVENTION

20 Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description.

The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Each
25 nucleotide or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in
30 the specification are defined by the information provided in numeric indicator field <400>

- 2 -

followed by the sequence identifier (eg. <400>1, <400>2, etc).

The designation of nucleotide residues referred to herein are those recommended by the IUPAC-IUB Biochemical Nomenclature Commission, wherein A represents Adenine, C represents Cytosine, G represents Guanine, T represents thymine, Y represents a pyrimidine residue, R represents a purine residue, M represents Adenine or Cytosine, K represents Guanine or Thymine, S represents Guanine or Cytosine, W represents Adenine or Thymine, H represents a nucleotide other than Guanine, B represents a nucleotide other than Adenine, V represents a nucleotide other than Thymine, D represents a nucleotide other than Cytosine and N represents any nucleotide residue.

The increasing sophistication of recombinant DNA technology is greatly facilitating research and development in the medical and allied health fields. This is particularly the case in the development of recombinant cytokines and growth factors for use in the treatment of diabetes, acquired immunodeficiency syndrome (AIDS) and a number of cancers.

However, despite this developing knowledge of cytokine and growth factor effector molecules, their full exploitation requires an understanding of the corresponding cellular receptors and the complex biochemical and physiological signalling pathways initiated following interaction with ligands or following other stimulation such as disease, receptor aggregation or trauma.

A number of soluble trophic factors have been shown to exhibit an effect on neuronal survival *in vivo*. Many of these factors act directly on the developing neuron within, for example, the dorsal root ganglia (DRG). One factor of particular importance is nerve growth factor (NGF) [1]. The p75 neurotrophin receptor (hereinafter referred to as "p75^{NTR}"), which is capable of complexing with trk growth factor receptors, is required for high affinity NGF binding and survival signalling. Although NGF has been proposed as a potential therapeutic molecule to promote survival of neurons, NGF is a multifunctional molecule and its pleiotrophy may adversely effect a range of non-neuronal cells.

- p75^{NTR} is also multifunctional. It has now been shown that p75^{NTR} is capable of acting as a death receptor. Elevated p75^{NTR} expression results in increased cell death *in vitro* and *in vivo* [2-4]. Furthermore, down-regulation of p75^{NTR} prevents neuronal death after growth-factor withdrawal or axotomy [5, 6]. Consistent with the dual functions of p75^{NTR}, mice with
- 5 deleted p75^{NTR} genes have a dramatic reduction of NGF dependent neurons, such as dorsal root ganglia, but increased numbers of other neuron populations (sympathetic and basal forebrain neurons) suggesting lack of naturally occurring cell death [7, 8]. p75^{NTR} is also implicated in mediating death of neuronal, oligodendrocytes and Schwann cells [8, 9].
- 10 p75^{NTR} is a member of the tumor necrosis factor (TNF) receptor/Fas superfamily, showing homology not only to the extracellular ligand binding domain but also to a cytoplasmic motif known as the "death domain", so termed because of the cytotoxic actions of proteins containing the domain [9].
- 15 There is an accumulating body of evidence which suggests that p75^{NTR} is involved in mediating cell death in a variety of degenerative diseases. During adulthood, p75^{NTR} expression is down-regulated in most brain areas but is rapidly induced in ischemia (stroke) and results in transient increased p75^{NTR} expression and apoptosis, as do both peripheral and motor nerve lesions [10-12]. p75^{NTR} is also up regulated in patients with MND [13], and in
- 20 experimental allergic encephalomyelitis (a model of multiple sclerosis; [14]). Intriguingly, in the basal forebrain and hippocampus, areas involved in learning and memory, p75^{NTR} is highly expressed in aged rodents and in Alzheimer's patients, where extensive neuronal death is occurring [15, 16]. These data suggest that p75^{NTR} is involved not only in normal developmental cell death, but may mediate the cell death occurring after injury or in
- 25 neurodegenerative disease.

In work leading up to the present invention, the inventors sought to elucidate the region on p75^{NTR} which mediates death signalling. The inventors surprisingly determined that the death signal is not the cytoplasmic motif known as the death domain [9] but is a region adjacent the

30 membrane domain on p75^{NTR}. The identification of this region provides for an opportunity to modulate cell survival by antagonising the death signalling region or promoting apoptosis by

providing cells with the genetic material to express the death signalling region adjacent, proximal or otherwise juxtaposed or associated with the membrane or to express the death signalling region in multimeric form.

5 SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other
10 element or integer or group of elements or integers.

One aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides which encodes an amino acid sequence which is capable of signalling, inducing or otherwise facilitating the death of a
15 cell in which said amino acid sequence is adjacent, proximal or otherwise juxtaposed to the membrane of said cell or when said amino acid sequence is in multimeric form.

Another aspect of the present invention is directed to a nucleic acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides which encodes a peptide,
20 polypeptide or protein capable of signalling, inducing or otherwise facilitating death of a cell in which it is expressed wherein said peptide, polypeptide or protein comprises a membrane associating portion and/or a multimer-forming portion and a portion which corresponds to all or part of the cytoplasmic region of p75^{NTR} or a functional equivalent, derivative or
homologue thereof.

25

Yet another aspect of the present invention contemplates homologues, analogues and derivatives of a nucleic acid molecule which encodes a peptide, polypeptide or protein which is capable of signalling inducing or otherwise facilitating death of a cell in which it is expressed wherein said peptide, polypeptide or protein comprises a membrane associating
30 portion and/or a multimer-forming portion and a portion which corresponds to all or part of the cytoplasmic region of p75^{NTR} or a functional equivalent, derivative or homologue thereof.

A further aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes an amino acid sequence which inhibits or reduces p75^{NTR}-mediated cell death wherein said amino acid sequence is a soluble form of the p75^{NTR} receptor corresponding to an intracellular region adjacent, proximal or otherwise
5 juxtaposed to the membrane of said cell.

Still another aspect of the present invention provides a nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence which is substantially as set forth in <400>3 or is a nucleotide sequence capable of hybridising thereto under low stringency
10 conditions at 42 °C or is a nucleotide sequence having at least 60% identity thereto.

Still yet another aspect of the present invention contemplates a nucleic acid molecule comprising a nucleotide sequence or a complementary form thereof, which nucleotide sequence encodes an amino acid sequence substantially as set forth in <400>4 or a derivative,
15 homologue or chemical equivalent thereof or an amino acid sequence having at least 60% identity thereto.

Even yet another aspect of the present invention provides a genetic construct comprising an isolated nucleic acid molecule which comprises a sequence of nucleotides which corresponds
20 or is complementary to a death signal region from p75^{NTR} or a homologue, analogue or derivative thereof.

Another aspect of the present invention contemplates an isolated peptide, polypeptide or protein comprising the cytoplasmic region of p75^{NTR} which signals, induces or otherwise
25 facilitates cell death when said peptide, polypeptide or protein is adjacent, proximal or otherwise juxtaposed to a membrane-associating region such as from p75^{NTR} or other membrane molecule and/or said peptide, polypeptide or protein is capable of forming multimers or a derivative, homologue, chemical equivalent or analogue of said peptide, polypeptide or protein. This aspect of the present invention does not extend to the full length
30 p75^{NTR}.

Still another aspect of the present invention contemplates a method for inhibiting, reducing or otherwise antagonising a p75^{NTR}-mediated death signal in a neuronal cell, said method comprising introducing a nucleic acid molecule capable of being expressed to an expression product which corresponds to a non-membrane associated form of the p75^{NTR} death signal region or a derivative, functional equivalent or homologue thereof.

Yet another aspect of the invention contemplates a method for inhibiting, reducing or otherwise antagonising a p75^{NTR}-mediated death signal in a neuronal cell, said method comprising contacting a cell carrying a p75^{NTR} with a death signal-inhibiting effective amount of a molecule capable of antagonising the death signal of p75^{NTR} or a component of the death signalling pathway.

Even still another aspect of the present invention provides a biological composition comprising a genetic molecule capable of being expressed into a p75^{NTR} death signal antagonist or a p75^{NTR} death signal.

Another aspect of the present invention is directed to a biological composition comprising a molecule capable of antagonising p75^{NTR}-mediated death signalling of a cell.

The terms "c35" and "35mer" are used interchangeably herein to refer to 35 amino acid domain juxtaposed to the membrane. When in soluble form, this peptide is referred to as soluble c35 or 35mer. The nucleotide and amino acid sequence of c35 are shown in <400>7 and <400>8, respectively. The term "29mer" refers to a truncated form of the 35mer. Six amino acids have been deleted from the C-terminal end. The nucleotide and amino acid sequence of 29mer are shown in <400>11 and <400>12, respectively.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a diagrammatic representation showing plasmid constructs with and without the death signalling region. The black region is the putative "death domain" [9] but which is not directly involved in p75^{NTR} mediated cell death.

Figure 2 is a graphical representation showing survival of DRG neurons 17 hours after microinjection and cultured in LIF. The data show that the amino acid domain juxtaposed to the membrane is required for death signalling rather than the putative "death domain" [9].

10

Figure 3 is a graphical representation showing DRG survival 16 hours after microinjection and cultured in LIF. The data show that over 90% of cells die when expressing the death signal linked to the membrane.

15 **Figure 4** is a graphical representation showing DRG survival 20 hours after microinjection and cultured in LIF. These data show that when the death signal is not associated with the membrane, that the ability to induce death is removed.

Figure 5 is a graphical representation showing that the c35 protein (i.e. p75^{NTR} death signal region) inhibits death signalling mediated by p75^{NTR}.

20

Figure 6 is a graphical representation showing that soluble c35 inhibits p75^{NTR}-mediated death signalling.

25 **Figure 7** is a graphical representation showing protection of membrane-bound killing-domain by a soluble 35 amino acid peptide and a soluble 29 amino acid peptide. The cells were subjected to microinjection of sp35 or GFP followed 30 minutes later by either peptide c35 or the 29mer peptide.

30 **Figure 8** is a graphical representation showing that peptide 29 which has a palmitoyl group at the membrane (amino) end and which facilitates association with the membrane mediates to

- 8 -

cell death. In contrast, the soluble 35 amino acid molecule tends to protect the cells. F, Fluoro tagged; pen, penetratin.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention arose in part following an investigation of the neurotrophin receptor, p75^{NTR}, in its capacity as a death signalling protein. Although the p75^{NTR} molecule comprises a putative death domain [9], in accordance with the present invention, this death domain is not directly associated with p75^{NTR}-mediated cell death. Rather, a region adjacent, proximal or otherwise juxtaposed to the membrane domain of p75^{NTR} is required for cell death. The nucleotide and corresponding amino acid sequence of the death domain [9] is shown in <400>9 and <400>10, respectively.

10

Accordingly, one aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides which encode an amino acid sequence which is capable of signalling, inducing or otherwise facilitating the death of a cell in which said amino acid sequence is adjacent, proximal or otherwise juxtaposed to the membrane of said cell or when said amino acid sequence is in multimeric form.

15

Reference herein to the signalling, inducing or otherwise facilitating the death of a cell or a death signal is meant to be construed in its broadest sense meaning that the amino acid sequence plays a role in a pathway leading to cell death. The death signal may also be regarded as an apoptotic signal. Although not wishing to limit the present invention to any one theory or mode of action, it is proposed herein that there is a pathway from p75^{NTR} activation to caspase activation and cellular degeneration. It is further proposed that p75^{NTR}-mediated cell death may occur directly or indirectly *via* Bcl-2.

20

25

The present specification refers interchangeably to death signal, death signal region, signalling, inducing or otherwise facilitating the death of a cell and c35.

The nucleic acid molecule of the present invention may encode a non-full length p75^{NTR} molecule although to facilitate cell death, the nucleic acid molecule must encode all or part of the cytoplasmic portion of the p75^{NTR} molecule and a sufficient amount of the membrane

30

domain such that the region referred to herein as the death signal is membrane associated. A "part" of the cytoplasmic domain of p75^{NTR} includes all or a death-inducing functional part of a 35 amino acid region juxtaposed to the membrane domain. Alternatively, the cytoplasmic domain of the p75^{NTR} molecule is in multimeric form or capable of forming multimers. A multimer comprises two or more copies of the molecule such as a dimer, trimer or larger copy molecule.

The term "membrane associated" means that the death signal is adjacent, proximal or otherwise juxtaposed to the membrane of a cell expressing the nucleic acid molecule.

10

The "death signal region" and other related terms are used herein to describe functionally the region of the cytoplasmic portion of p75^{NTR} which is adjacent, proximal or otherwise juxtaposed to a region of p75^{NTR} which associates with the membrane or which cytoplasmic portion is in multimeric form. The death signal region is not the same portion of the molecules as the "death domain" [9] although there may be functional similarities in death signalling.

Accordingly, another aspect of the present invention is directed to a nucleic acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides which encodes a peptide, polypeptide or protein capable of signalling, inducing or otherwise facilitating death of a cell in which it is expressed wherein said peptide, polypeptide or protein comprises a membrane associating portion and/or a multimer-forming portion and a portion which corresponds to all or part of the cytoplasmic region of p75^{NTR} or a functional equivalent, derivative or homologue thereof.

25

In order to signal, induce or otherwise facilitate death of a cell, the death signal region is preferably adjacent, proximal or otherwise juxtaposed to the cell membrane. This may be facilitated by modifying a peptide such that it associates with the membrane. One example of this type of modification is palmitoylation. This puts a palmitoyl group at the membrane (amino) end of the peptide. The present invention also extends to multimeric forms and attachments which facilitate same. A multimer comprises two or more molecules.

30

In one embodiment, the membrane portion is derived from p75^{NTR} or a functional equivalent, derivative or homologue thereof. In another embodiment, the membrane domain is from another molecule such as a receptor or other ligand-binding molecule. Examples of receptors according to this aspect of the present invention include cytokine receptors (e.g. the
5 Leukaemia Inhibitory Factor (LIF) receptor, interleukin receptor, and colony-stimulating factor receptors). Examples of ligand-binding molecules include immunoglobulins and T cell receptors.

When in multimeric form, the molecule is only optionally associated with the membrane to
10 effect cell death.

The nucleic acid molecule may comprise cDNA or genomic DNA or may comprise ribonucleotides such as mRNA. The nucleic acid molecule may be derived from a cDNA or genomic molecule encoding p75^{NTR} or a derivative or homologue thereof or may be prepared
15 by the stepwise addition of nucleotides in a defined sequence.

The nucleic acid molecule of the present invention may also be considered as corresponding to a "gene".

20 Reference herein to a "gene" is to be taken in its broadest context and includes:

- (i) a classical genomic gene consisting of transcriptional and/or translational regulatory sequences and/or a coding region and/or non-translated sequences (i.e. introns, 5'- and 3'- untranslated sequences);
- (ii) mRNA or cDNA corresponding to the coding regions (i.e. exons) optionally
25 comprising 5'- or 3'-untranslated sequences of the gene; or
- (iii) an amplified DNA fragment or other recombinant nucleic acid molecule produced *in vitro* and comprising all or a part of the coding region and/or 5'- or 3'- untranslated sequences of the gene.

30 The term "gene" is also used to describe synthetic or fusion molecules encoding all or part of a functional product. A functional product is one which comprises a sequence of nucleotides

or is complementary to a sequence of nucleotides which encodes a functional death signal from p75^{NTR} or its derivative or homologue.

The nucleotide sequence of the present invention may correspond to the cDNA or genomic
5 sequence of a gene encoding p75^{NTR} or a death signal region thereof or may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or additions. Nucleotide insertional derivatives of the nucleic acid molecule of the present invention include 5' and 3' terminal fusions as well as intra-sequence insertions of single or multiple nucleotides. Insertional nucleotide sequence variants are those in which one or more
10 nucleotides are introduced into a predetermined site in the nucleotide sequence although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterised by the removal of one or more nucleotides from the sequence. Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide inserted in its place. Such a substitution may be
15 "silent" in that the substitution does not change the amino acid defined by the codon. Alternatively, substituents are designed to alter one amino acid for another similar acting amino acid, or amino acid of like charge, polarity, or hydrophobicity.

Accordingly, another aspect of the present invention contemplates homologues, analogues
20 and derivatives of a nucleic acid molecule which encodes a peptide, polypeptide or protein which is capable of signalling, inducing or otherwise facilitating death of a cell in which it is expressed wherein said peptide, polypeptide or protein comprises a membrane associating portion and/or multimer-forming portion and a portion which corresponds to all or part of the cytoplasmic region of p75^{NTR} or a functional equivalent, derivative or homologue thereof.

25

For the present purpose, "homologues" of a nucleic acid molecule as herein defined or of a nucleotide sequence shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as the nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence within said sequence, of
30 one or more nucleotide substitutions, insertions, deletions, or rearrangements.

"Analogues" of a nucleic acid molecule as herein defined or of a nucleotide sequence set forth herein shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as a nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence of any non-nucleotide constituents not normally
5 present in said isolated nucleic acid molecule, for example carbohydrates, radiochemicals including radionucleotides, reporter molecules such as, but not limited to DIG, alkaline phosphatase or horseradish peroxidase, amongst others.

"Derivatives" of a nucleic acid molecule as herein defined or of a nucleotide sequence set
10 forth herein shall be taken to refer to any isolated nucleic acid molecule which contains significant sequence similarity to said sequence or a part thereof. Generally, the nucleotide sequence of the present invention may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or insertions. Nucleotide insertional derivatives of the nucleotide sequence of the present invention include 5' and 3' terminal
15 fusions as well as intra-sequence insertions of single or multiple nucleotides or nucleotide analogues. Insertional nucleotide sequence variants are those in which one or more nucleotides or nucleotide analogues are introduced into a predetermined site in the nucleotide sequence of said sequence, although random insertion is also possible with suitable screening of the resulting product being performed. Deletional variants are characterised by the
20 removal of one or more nucleotides from the nucleotide sequence. Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide or nucleotide analogue inserted in its place.

In one embodiment, the derivatives encode a peptide, polypeptide or protein which induces
25 cell death. In another embodiment, the derivatives do not induce cell death but antagonise the death signal.

According to this latter embodiment, there is provided an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes an amino acid sequence which inhibits
30 or reduces p75^{NTR}-mediated cell death wherein said amino acid sequence is a soluble form of the p75^{NTR} receptor corresponding to an intracellular region adjacent, proximal or otherwise

juxtaposed to the membrane of said cell.

The nucleic acid molecule of the present invention may be based on a nucleotide sequence of the gene or cDNA encoding p75^{NTR} from any animal such as from mammals. Preferred
5 mammals include humans, primates, livestock animals (e.g. cows, sheep, horses, pigs, donkeys, goats), laboratory test animals (e.g. rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g. dogs, cats) and captive wild animals.

A particularly preferred sequence is from human or primate or murine p75^{NTR}.

10

The present invention is exemplified using a nucleotide sequence from rat p75^{NTR} cDNA. This is done, however, with the understanding that the nucleotide sequence may be from p75^{NTR} genomic or cDNA from any animal.

15 Accordingly, another aspect of the present invention provides a nucleic acid molecule comprising a nucleotide sequence or a complementary form thereof wherein said nucleotide sequence is capable of hybridising to <400>1 under low stringency conditions at 42 °C.

The nucleotide sequence set forth in <400>1 is the cDNA sequence encoding p75^{NTR}. The
20 nucleic acid molecule according to this aspect of the present invention does not extend to the full length p75^{NTR} cDNA sequence but comprises a portion which encodes an amino acid sequence which signals, induces or otherwise facilitates cell death when associated with a membrane portion of p75^{NTR} or other molecules.

25 Accordingly, another aspect of the present invention provides a nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence which is substantially as set forth in <400>7 or is a nucleotide sequence capable of hybridising thereto under low stringency conditions at 42 °C or is a nucleotide sequence having at least 60% identity thereto.

30

The nucleotide sequence set forth in <400>7 is the death signal defined herein associated

with p75^{NTR}. This sequence encodes a 35 amino acid region also referred to herein as "c35". Truncated forms of c35 are also contemplated by the present invention such as a 25-30 amino acid molecules. One particular example is a 29mer.

- 5 Reference herein to a low stringency at 42°C includes and encompasses from at least about 0% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about
- 10 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

15

The present invention further contemplates a nucleic acid molecule comprising a nucleotide sequence or a complementary form thereof, which nucleotide sequence encodes an amino acid sequence substantially as set forth in <400>8 or a derivative, homologue or chemical equivalent thereof or an amino acid sequence having at least 60% identity thereto.

20

The amino acid sequence of <400>8 corresponds to the amino acid sequence of the p75^{NTR} death signal.

- The term "identity" as used herein includes exact identity between compared sequences at the
- 25 nucleotide or amino acid level. Where there is non-identity at the nucleotide level, the term "similarity" may also be used and includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the
- 30 structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide and sequence comparisons are made at the level of identity rather

than similarity. Any number of programs are available to compare nucleotide and amino acid sequences. Preferred programs have regard to an appropriate alignment. One such program is Gap which considers all possible alignment and gap positions and creates an alignment with the largest number of matched bases and the fewest gaps. Gap uses the alignment method of Needleman and Wunsch [17]. Gap reads a scoring matrix that contains values for every possible GCG symbol match. GAP is available on ANGIS (Australian National Genomic Information Service) at website <http://mell1.angis.org.au>.

The present invention further comprises a nucleic acid molecule comprising the nucleotide sequence:

$$\{n_1 - \dots - n_x\}_b \text{ a } \{n'_1 - \dots - n'_y\}_c \text{ a } \{n''_1 - \dots - n''_z\}_d$$

wherein

$\{n_1 - \dots - n_x\}$ is a sequence of x nucleotides encoding an extracellular portion of a receptor or ligand-binding molecule;

$\{n'_1 - \dots - n'_y\}$ is a sequence of y nucleotides encoding a transmembrane peptide, polypeptide or protein or a molecule capable of inducing multimerisation;

$\{n''_1 - \dots - n''_z\}$ is a sequence of z nucleotides comprising a nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence encoding an amino acid sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising thereto under low stringency conditions at 42 °C or a nucleotide sequence having at least 60% identity to <400>7;

b, c and d may be the same or different and each is 0, 1 or >1;

x, y and z may be the same or different and each is 0, 1 or >1;

a is a nucleotide bond;

wherein when c is 1 or >1 and d is 1 or >1 and wherein when the molecule is

expressed in a neuronal cell, the expression product signals, induces or otherwise facilitates cell death.

Preferably, $\{n_1 - - - n_x\}$ comprises the nucleotide sequence substantially as set forth in
5 <400>3 or is a nucleotide sequence having at least about 60% identity thereto or is capable of hybridising thereto under low stringency conditions at 42 °C.

Preferably, $\{n'_1 - - - n'_y\}$ comprises the nucleotide sequence substantially as set forth in
10 <400>5 or is a nucleotide sequence having at least about 60% identity thereto or is capable of hybridising thereto under low stringency conditions at 42 °C.

The nucleotide sequences $\{n_1 - - - n_x\}$, $\{n'_1 - - - n'_y\}$ and $\{n''_1 - - - n''_z\}$ may be in any order and in any combination.

15 For the production of a recombinant peptide, polypeptide or protein comprising the death signal, the nucleic acid molecule of the present invention is placed, in the sense orientation, in operable connection with a suitable promoter sequence and introduced into a suitable expression system, for example a bacterial, yeast, baculovirus, plant, animal or other expression system.

20

Accordingly, a further aspect of the present invention provides a genetic construct comprising an isolated nucleic acid molecule which comprises a sequence of nucleotides which corresponds or is complementary to a death signal region from p75^{NTR} or a homologue, analogue or derivative thereof.

25

According to this embodiment, the coding region of the death signal from p75^{NTR} may be placed in operable connection with a promoter sequence such that a gene product is capable of being expressed under the control of said promoter sequence.

30 Optionally, said genetic construct further comprises a terminator sequence.

In the present context, the term "in operable connection with" is used to indicate that expression of the isolated nucleotide sequence is under the control of the promoter sequence with which it is connected.

- 5 The term "terminator" refers to a DNA sequence at the end of a transcriptional unit which signals termination of transcription. Terminators are 3'-non-translated DNA sequences containing a polyadenylation signal, which facilitates the addition of polyadenylate sequences to the 3'-end of a primary transcript. Terminators active in plant cells are known and described in the literature. They may be isolated from bacteria, fungi, viruses, animals and/or
10 plants.

Examples of terminators particularly suitable for use in the genetic constructs of the present invention include the SV40 polyadenylation signal, amongst others.

- 15 Reference herein to a "promoter" is to be taken in its broadest context and includes the transcriptional regulatory sequences of a classical genomic gene, including the TATA box which is required for accurate transcription initiation in eukaryotic cells, with or without a CCAAT box sequence and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers). For expression in prokaryotic cells, such as bacteria, the promoter
20 should at least contain the -35 box and -10 box sequences.

A promoter is usually, but not necessarily, positioned upstream or 5', of the nucleotide sequence encoding the death signal of p75^{NTR}, the expression of which it regulates.

- Furthermore, the regulatory elements comprising a promoter are usually positioned within 2
25 kb of the start site of transcription of the gene.

In the present context, the term "promoter" is also used to describe a synthetic or fusion molecule, or derivative which confers, activates or enhances expression of an isolated nucleic acid molecule, in a cell, such as a plant, animal, insect, fungal, yeast or bacterial cell.

- 30 Preferred promoters may contain additional copies of one or more specific regulatory elements, to further enhance expression of a nucleic acid molecule which expression it

regulates and/or to alter the spatial expression and/or temporal expression of same. For example, regulatory elements which confer copper inducibility may be placed adjacent to a heterologous promoter sequence driving expression of a nucleic acid molecule, thereby conferring copper inducibility on the expression of said molecule.

5

Placing an isolated nucleic acid molecule under the regulatory control of a promoter sequence means positioning said molecule such that expression is controlled by the promoter sequence. Promoters are generally positioned 5' (upstream) to the genes that they control. In the construction of heterologous promoter/structural gene combinations it is generally preferred
10 to position the promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting, i.e., the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of promoter function. Similarly, the preferred positioning of a regulatory sequence element with respect to a
15 heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting, i.e., the genes from which it is derived. Again, as is known in the art, some variation in this distance can also occur.

Examples of promoters suitable for use in genetic constructs of the present invention include
20 viral, fungal, bacterial, animal and plant derived promoters capable of functioning in plant, animal, insect, fungal, yeast or bacterial cells. The promoter may regulate the expression of the nucleic acid molecule constitutively, or differentially with respect to the tissue in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, or plant pathogens, or metal
25 ions, amongst others.

Preferably, the promoter is capable of regulating expression of a nucleic acid molecule in a yeast or bacterial cell.

30 Examples of preferred promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, *lac* promoter, *tac* promoter, SV40 early promoter, and the like.

The genetic construct contemplated herein is introduced into a suitable expression system for a time and under conditions sufficient for expression of said death signal from p75^{NTR} to occur.

- 5 The genetic construct may also comprising a nucleotide sequence corresponding to all or part of the membrane domain of p75^{NTR} or other membrane molecules.

Accordingly, a further aspect of the invention contemplates a recombinant peptide, polypeptide or protein produced by expressing the isolated nucleic acid molecule herein
10 described in a suitable host cell. The present invention extends also to a synthetic peptide fragment of said recombinant gene product.

The present invention further contemplates an isolated peptide, polypeptide or protein comprising the cytoplasmic region of p75^{NTR} which signals, induces or otherwise facilitates
15 cell death when said peptide, polypeptide or protein is adjacent, proximal or otherwise juxtaposed to a membrane-associating region such as from p75^{NTR} or other membrane molecule and/or is in multimeric form or a derivative, homologue, chemical equivalent or analogue of said peptide, polypeptide or protein. This aspect of the present invention does not extend to the full length p75^{NTR}.

20

Suitable molecules according to this aspect of the present invention include a peptide, polypeptide or protein corresponding to a soluble form of the death signalling region of p75^{NTR} or a molecule capable of antagonising that region or a component of the death signalling pathway. An example of a component of the death signalling pathway is Bcl-2.

25

The peptide, polypeptide or protein of this aspect of the present invention is useful *inter alia* as a therapeutic molecule to antagonise p75^{NTR}-mediated death signalling. For example, the peptide, polypeptide or protein may themselves be administered to directly antagonise p75^{NTR}-mediated death signalling or the peptide, polypeptide or protein may need to be
30 chemically modified to facilitate penetration into the cell. Alternatively, the death signalling region of p75^{NTR} may be used to screen for antagonists of this region. Such antagonists may,

for example, be identified following natural product screening or the screening of chemical libraries. For natural product screening suitable environments include, but are not limited to, plants, bacteria and other microorganisms, river and sea beds, coral and arctic or antarctic regions. The present invention also contemplates antagonists directed to other components
5 of the p75^{NTR}-mediated death signalling pathway. Such components to be targeted include but are not limited to Bcl-2 or related or homologous molecules.

Preferably, the peptide, polypeptide or protein comprises an amino acid sequence substantially as set forth in <400>8 or an amino acid sequence having at least 60% identity
10 thereto or a chemical equivalent, derivative, homologue or analogue of said peptide, polypeptide or protein.

The term "isolated" means that the peptide, polypeptide or protein of the present invention is provided in a form which is distinct from that which occurs in nature, preferably wherein one
15 or more contaminants have been removed. Accordingly, the isolated peptide, polypeptide or protein of the invention may be partially-purified or substantially pure, in which a substantial amount of the contaminants have been removed or in sequencably pure or substantially homogeneous form.

20 The term "sequencably pure" means that the isolated peptide, polypeptide or protein is provided in a form which is sufficiently purified to facilitate amino acid sequence determination using procedures known to those skilled in the art.

The term "substantially homogeneous" means that the isolated peptide, polypeptide or
25 protein of the present invention is at least about 95% free of contaminants, more preferably at least about 99% free of contaminants, including 100% purity.

The present invention extends to a range of derivatives and chemical analogues of the peptide, polypeptide or protein.

30

Furthermore, the amino acids of a homologous polypeptide may be replaced by other amino

acids having similar properties, for example hydrophobicity, hydrophilicity, hydrophobic moment, charge or antigenicity, and so on.

"Analogues" encompass death signal containing peptides, polypeptides or proteins which are
 5 at least about 60% identical to the p75^{NTR} death signal sequence [<400>8], notwithstanding the occurrence of any non-naturally occurring amino acid analogues therein. "Analogues" also encompass polypeptide mimotypes.

The term "derivative" in relation to a peptide, polypeptide or protein shall be taken to refer
 10 hereinafter to mutants, parts or fragments derived from the functional p75^{NTR} molecule or death signal region thereof or derivatives thereof which may or may not possess the death signal activity of the functional p75^{NTR}. Derivatives include modified peptides in which ligands are attached to one or more of the amino acid residues contained therein, such as carbohydrates, enzymes, proteins, polypeptides or reporter molecules such as radionuclides
 15 or fluorescent compounds. Glycosylated, fluorescent, acylated or alkylated forms of the subject peptides are particularly contemplated by the present invention. Additionally, derivatives of the peptide, polypeptide or protein described herein comprise fragments or parts of an amino acid sequence disclosed herein are within the scope of the invention, as are homopolymers or heteropolymers comprising two or more copies of the subject polypeptides.
 20 Procedures for derivatizing peptides are well-known in the art.

A homologue, analogue or derivative of <400>2 or <400>8 may comprise an amino acid substitution or said <400> 2 or 8 may encompass amino acid alterations in which an amino acid is replaced with a different naturally-occurring or a non-conventional amino acid residue.
 25 Such substitutions may be classified as "conservative", in which case an amino acid residue contained in a phospholipase inhibitory protein is replaced with another naturally-occurring amino acid of similar character, for example Gly↔Ala, Val↔Ile↔Leu, Asp↔Glu, Lys↔Arg, Asn↔Gln or Phe↔Trp↔Tyr.

30 Substitutions encompassed by the present invention may also be "non-conservative", in which an amino acid residue which is present in a phospholipase inhibitory protein is substituted

with an amino acid having different properties, such as a naturally-occurring amino acid from a different group (eg. substituted a charged or hydrophobic amino acid with alanine), or alternatively, in which a naturally-occurring amino acid is substituted with a non-conventional amino acid.

5

Amino acid substitutions are typically of single residues, but may be of multiple residues, either clustered or dispersed.

Naturally-occurring amino acids include those listed in Table 1. Non-conventional amino
10 acids encompassed by the invention include, but are not limited to those listed in Table 2.

Amino acid deletions will usually be of the order of about 1-10 amino acid residues, while insertions may be of any length. Deletions and insertions may be made to the N-terminus, the C-terminus or be internal deletions or insertions. Generally, insertions within the amino acid
15 sequence will be smaller than amino-or carboxyl-terminal fusions and of the order of 1-4 amino acid residues.

TABLE 1

5	Amino Acid	Three-letter	One-letter
		Abbreviation	Symbol
	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
10	Aspartic acid	Asp	D
	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamic acid	Glu	E
	Glycine	Gly	G
15	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
	Methionine	Met	M
20	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
	Threonine	Thr	T
	Tryptophan	Trp	W
25	Tyrosine	Tyr	Y
	Valine	Val	V
	Any amino acid as above	Xaa	X

TABLE 2

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
5				
	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane- carboxylate	Cpro	L-N-methylasparagine	Nmasn
			L-N-methylaspartic acid	Nmasp
10	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl- carboxylate	Norb	L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
15	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Das	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
20	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
25	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
30	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva

	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgabu
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
5	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
10	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
15	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
20	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
25	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl) glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl) glycine	Nbhe



- 27 -

	D-N-methylglutamine	DnmglN	N-(3-guanidinopropyl) glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
5	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl) glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl) glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
10	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmt
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpn
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
15	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
20	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
25	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomo phenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl) glycine	Nmet
30	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys

- 28 -

L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
L- α -methylserine	Mser	L- α -methylthreonine	Mthr
5 L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
L- α -methylvaline	Mval	L-N-methylhomo	
		phenylalanine	Nmhpe
N-(N-(2,2-diphenylethyl)		N-(N-(3,3-diphenylpropyl)	
carbamylmethyl)glycine	Nnbhm	carbamylmethyl)glycine	Nnbhe
10 1-carboxy-1-(2,2-diphenyl-			
ethylamino)cyclopropane	Nmbc		

The present invention provides for a method of treatment or prophylaxis of disease
 15 conditions associated with neuronal death or where cell death is to be promoted such as in
 treating or preventing cancer growth and/or development.

In one embodiment, it has been determined in accordance with the present invention that
 expression of a nucleic acid molecule encoding only death signal and not adjacent, proximal
 20 or juxtaposed to a membrane-associating sequence results in antagonising of the death signal.

According to this embodiment, the present invention contemplates a method for inhibiting,
 reducing or otherwise antagonising a p75^{NTR}-mediated death signal in a neuronal cell, said
 method comprising introducing a nucleic acid molecule capable of being expressed to an
 25 expression product which corresponds to a non-membrane associated form of the p75^{NTR}
 death signal region or a derivative, functional equivalent or homologue thereof.

In a related embodiment there is provided a method for inhibiting, reducing or otherwise
 antagonising a p75^{NTR}-mediated death signal in a neuronal cell, said method comprising
 30 contacting a cell carrying a p75^{NTR} with a death signal-inhibiting effective amount of a
 molecule capable of antagonising the death signal of p75^{NTR} or a component of the death



signalling pathway.

This aspect of the present invention is useful for the treatment of a range of neurodegenerative diseases such as cerebral palsy, trauma induced paralysis, vascular
5 ischaemia associated with stroke, neuronal tumours, motoneurone disease, Parkinson's disease, Huntington's disease, Alzheimer's disease, multiple sclerosis and peripheral neuropathies associated with diabetes, heavy metal or alcohol toxicity, renal failure and/or infectious diseases such as herpes, rubella, measles, chicken pox, HIV and/or HTLV-1. This aspect is also useful for treating neurons damaged by trauma or disease.

10

Alternatively, the method is aimed at targeting certain cells such as cancer cells wherein expression is required of a death signal from p75^{NTR} or a derivative, functional equivalent or homologue thereof adjacent, proximal or otherwise juxtaposed to a membrane-associating portion of p75^{NTR} or other membrane molecules or is in multimeric form. The nucleic acid
15 molecule may require modification to ensure appropriate targeting to the cell or the nucleic acid molecule may be injected directly into cancerous tissue.

Another aspect of the present invention provides a biological composition comprising a genetic molecule capable of being expressed into a p75^{NTR} death signal antagonist or a p75^{NTR}
20 death signal. The biological composition further comprises one or more pharmaceutically acceptable carriers and/or diluents. The nucleic acid molecules according to this aspect of the present invention may be naked nucleic acid molecules or contained or associated with a viral vector or other suitable delivery mechanism.

25 Another aspect of the present invention is directed to a biological composition comprising a molecule capable of antagonising p75^{NTR}-mediated death signalling of a cell.

Suitable molecules according to this aspect of the present invention are as contemplated above and include a peptide, polypeptide or protein comprising a soluble form of the p75^{NTR}
30 death signalling region or an antagonist of a component of the p75^{NTR} death signalling pathway.

The present invention is also useful as a culture agent such as preventing or reducing the death of cells *in vitro*. The present invention is particularly useful *in vitro* when used in combination with LIF. Even more particularly, the present invention is useful for culturing recombinant cell lines.

5

The present invention also provides for the use of the death signal of p75^{NTR} in the manufacture of a medicament for the treatment of neurodegenerative diseases in animals. Preferred animals include humans, primates, livestock animals, laboratory test animals, companion animals and captive wild animals.

10

The present invention is further described by the following non-limiting Examples.

EXAMPLE 1

The aim of this example was to determine the protein domains on p75^{NTR} responsible for
5 death signalling.

In order to investigate how p75^{NTR} signals neuronal death, the inventors devised a robust *in vitro* assay for p75^{NTR} induced death. Plasmid expression constructs were microinjected into individual neurons in the presence of the growth factor LIF, and the survival of the neurons
10 expressing the different plasmids was determined. A series of plasmid constructs which encode incomplete p75^{NTR} proteins were made (see Figure 1) and the ability of each protein to signal death when over expressed was assessed.

The p75^{NTR} protein is a transmembrane protein comprised of a large extracellular domain
15 with four cysteine rich motifs responsible for interacting with soluble growth factors, and a short cytoplasmic, intracellular tail. The cytoplasmic domain does not contain a kinase domain but contains a domain with significant homology to a motif known as a "death domain" [<400>9, <400>10], found in apoptosis-inducing Tumour Necrosis Factor Receptors (TNFR) and TNFR-associating death-effector proteins [9].

- 32 -

Using expression plasmids of p75^{NTR} proteins deleted for either the entire cytoplasmic domain (p75nc) or a significant portion of the cytoplasmic domain including the entire death domain (p75tm), the inventors found that the cytoplasmic domain is responsible for death signalling. Surprisingly, the intracellular 35 amino acid domain juxtaposed to the membrane, and not the
5 death domain, is responsible for death signalling (Figure 2). This region of the p75^{NTR} protein shows no homology to other death inducing proteins or to known functional motifs.

To further investigate the domain required for death signalling the inventors made constructs expressing p75^{NTR} proteins deleted for the extracellular domain or the extracellular and
10 transmembrane domains. Proteins without extracellular domains retain the signal peptide which is responsible for correctly transporting the protein into the cell membrane. Proteins without transmembrane domains are expressed free in the cytoplasm of the cell and are epitope tagged with a FLAG motif for detection.

15 The inventors found that the extracellular domain of p75^{NTR} had a significant inhibitory effect of the ability of the cytoplasmic domain to signal cell death. Furthermore, the membrane linked 35 amino acid cytoplasmic domain (c35) was a potent stimulant of neuronal death with over 90% of cells injected with the plasmid dead after 16 hours (Figure 3). However, if the cytoplasmic 35 amino acid domain is not associated with the membrane, the ability of the
20 domain to induce death is removed (Figure 4).

These results indicate that the domain responsible for death induction is within the first 35 amino acids of the cytoplasmic tail but that the transmembrane domain, or at least association with the membrane, is required for death-signal activation. This may be related to the ability
25 of the transmembrane protein to more efficiently form death-signal inducing multimers, or that the position of the p75^{NTR} protein in relation to other membrane-bound accessory molecules might be important in initiating death signalling.

The inventors hypothesised that the free cytoplasmic expressed 35 amino acid domain might
30 be able to interfere with death signalling from full length p75^{NTR} proteins by a dominant-negative mechanism, and attempted to inhibit the death by co-expressing the proteins. Given

- 33 -

the results presented below regarding the ability of overexpression of Bcl-2 to enhance p75^{NTR} killing, this paradigm was used to test the ability of the c35 protein to inhibit death signalling. The inventors found that indeed the expression of the c35 protein was able to inhibit this killing (Figure 5). This further indicates that p75^{NTR} signals killing *via* interaction
 5 of an accessory molecule to a motif within the first 35 amino acids of the cytoplasmic domain.

EXAMPLE 2

The aim of this example is to determine the minimum number of amino acid residues on c35
 10 require to mediate death signalling.

A series of deletion and truncation mutants in the c35 region are produced and tested for the ability to induce death signalling.

15 The deletion mutants from the membrane distal end are as follows:

KRWNSCKQNKQGANSRPVNQTPPPEGEKLHSDSG;
 KRWNSCKQNKQGANSRPVNQTPPPEGEKLHSDS;
 KRWNSCKQNKQGANSRPVNQTPPPEGEKLHSD;
 20 KRWNSCKQNKQGANSRPVNQTPPPEGEKLHS;
 KRWNSCKQNKQGANSRPVNQTPPPEGEKLH;
 KRWNSCKQNKQGANSRPVNQTPPPEGEKL;
 KRWNSCKQNKQGANSRPVNQTPPPEGEK;
 KRWNSCKQNKQGANSRPVNQTPPPEGE;
 25 KRWNSCKQNKQGANSRPVNQTPPPEG;
 KRWNSCKQNKQGANSRPVNQTPPPE;
 KRWNSCKQNKQGANSRPVNQTPPP;
 KRWNSCKQNKQGANSRPVNQTPP;
 KRWNSCKQNKQGANSRPVNQTP;
 30 KRWNSCKQNKQGANSRPVNQT;
 KRWNSCKQNKQGANSRPVNQ;

- 34 -

KRWNSCKQNKQGANSRPVN;

KRWNSCKQNKQGANSRPV;

KRWNSCKQNKQGANSRP;

KRWNSCKQNKQGANSR;

5 KRWNSCKQNKQGANS;

KRWNSCKQNKQGAN;

KRWNSCKQNKQGA;

KRWNSCKQNKQG;

KRWNSCKQNKQ;

10 KRWNSCKQNK;

KRWNSCKQN;

KRWNSCKQ;

KRWNSCK;

KRWNSC;

15 KRWNS;

KRWN;

KRW;

KR; and

K.

20

The deletion mutants from the membrane proximal end are as follows:

RWNSCKQNKQGANSRPVNQTPPPEGEKLHSDSGI;

WNSCKQNKQGANSRPVNQTPPPEGEKLHSDSGI;

25 NSCKQNKQGANSRPVNQTPPPEGEKLHSDSGI;

SCKQNKQGANSRPVNQTPPPEGEKLHSDSGI;

CKQNKQGANSRPVNQTPPPEGEKLHSDSGI;

KQNKQGANSRPVNQTPPPEGEKLHSDSGI;

QNKGANSRPVNQTPPPEGEKLHSDSGI;

30 NKQGANSRPVNQTPPPEGEKLHSDSGI;

KQGANSRPVNQTPPPEGEKLHSDSGI;

- 35 -

QGANSRPVNQTPPPEGEKLHSDSGI;
GANSRPVNQTPPPEGEKLHSDSGI;
ANSRPVNQTPPPEGEKLHSDSGI;
NSRPVNQTPPPEGEKLHSDSGI;
5 SRPVNQTPPPEGEKLHSDSGI;
RPVNQTPPPEGEKLHSDSGI;
PVNQTPPPEGEKLHSDSGI;
VNQTPPPEGEKLHSDSGI;
NQTPPPEGEKLHSDSGI;
10 QTPPPEGEKLHSDSGI;
TPPPEGEKLHSDSGI;
PPPEGEKLHSDSGI;
PPEGEKLHSDSGI;
PEGEKLHSDSGI;
15 EGEKLHSDSGI;
GEKLHSDSGI;
EKLHSDSGI;
KLHSDSGI;
LHSDSGI;
20 HSDSGI;
SDSGI;
DSGI;
SGI;
GI; and
25 I.

- 36 -

EXAMPLE 3**ROLE OF BCL-2 IN PROMOTING p75^{NTR} MEDIATED DEATH SIGNALLING**

As the inventors had shown that the death of dorsal root ganglia (DRG) sensory neurons *in vitro* and *in vivo*, was, at least in part, mediated by p75^{NTR}, p75^{NTR} was over-expressed in these cells by microinjecting rat p75^{NTR} cDNA expressing plasmid into the nucleus of mouse sensory neurons. These were cultured in the presence of the LIF to prevent neuronal death not linked to p75^{NTR} mechanisms. It was found that the expression of the rat p75^{NTR} could be detected by surface immunofluorescence within 24 hours of injection. The injected neurons were observed over a 48 hour period and the viability was assessed. It was found that within the first 16 hours, a significantly higher number of p75^{NTR} plasmid injected neurons had died compared to neurons injected with control plasmids β -galactosidase, or a truncated p75^{NTR} protein lacking the entire cytoplasmic domain (p75^{NTR}nc). It was found that p75^{NTR}-mediated neuronal death occurred later in the experiment similar to Fas/TNF-induced rapid cell death. Since both full-length p75^{NTR} and p75^{NTR}nc protein showed a similar level of expression after injection, this indicates that the cytoplasmic domain of p75^{NTR} is required for death signalling. This was expected since the cytoplasmic tail contains a sequence with homology to the Fas/TNFR "death domain" [9].

The inventors next examined whether deletion of the "death domain" also abolished the ability of p75^{NTR} to kill. It was found that the neuronal death observed after expression of p75^{NTR} with a truncated cytoplasmic tail (p75^{NTR}tr) was equivalent to the full-length p75^{NTR} protein. This demonstrated that the "death domain" was not required for p75^{NTR} killing and, since the p75^{NTR} death domain has recently been shown to have a different tertiary structure to TNFR family death domain and does not self-associate *in vitro*, it suggests that the p75^{NTR} "death domain" may not normally function to induce death. Together, these results predict that an alternative pathway involving proteins other than "death domain" adapter proteins, such as TRADD and FADD, is responsible for p75^{NTR}-mediated killing.

The Bcl-2 family of proteins is involved in mediating apoptotic signalling pathways, and can homodimerise or heterodimerise with other family members. Bcl-2 and Bcl-xL are well characterised inhibitors of stress-induced apoptosis, JNK activation and neuronal death due to growth-factor limitation. However, both are poor inhibitors of Fas and TNFR mediated
5 opoptosis. As it had been shown previously that high levels of Bcl-2 or Bcl-xL blocked neuronal cell death in a variety of models, the inventors examined whether over-expression of these proteins could block the death induced by p75^{NTR}.

The inventors found that over-expression of Bcl-xL protected neurons against p75^{NTR}-
10 induced death, supporting the hypothesis that p75^{NTR} signals through an alternative pathway to TNFR-induced apoptosis. In contrast, while Bcl-2 over-expression alone had no effect on cell survival in the presence of LIF, Bcl-2 in combination with p75^{NTR} over-expression, surprisingly, induced a significant increase in neuronal death above that seen with p75^{NTR} over-expression alone. Bcl-2 in combination with p75^{NTR}nc did not cause significant cell
15 death and furthermore, the cell death observed with p75^{NTR} and Bcl-2 over-expression was totally ablated if the cells were cultured in NGF. Bcl-2 was able to protect against neuronal death induced by NGF withdrawal, but not withdrawal of LIF. Thus, at the same expression levels in the same neuronal population, Bcl-2 was able to prevent or enhance neuronal cell death depending on the nature of the death signal.

20

These results are surprising since Bcl-2 has previously been shown to have similar actions to Bcl-xL in almost all cell-death systems.

To determine whether the paradoxical effect of Bcl-2 on p75^{NTR}-induced killing was related
25 to its known anti-apoptotic activity, Bcl-2 proteins with inactivating point mutation, G145E, in the "Bcl-2 Homology" BH1 domain and W188A in the BH2 domain were utilised. Like wildtype Bcl-2, expression of either Bcl-2 mutant alone did not effect neuronal survival. In combination with p75^{NTR} expression, the enhanced killing effect seen with Bcl-2 co-expression was abrogated by the G145E mutation, even though the proteins were expressed
30 to comparable levels. Thus, an intact BH1 homology region is required for the death promoting activity of Bcl-2.

Mutation of the equivalent G138 residue in Bcl-xL results in a conformational change between α -helices 4 and 5, disrupting access to the hydrophobic cleft formed by BH1, BH2 and BH3 domains. Therefore, the molecular mechanism by which Bcl-2 participates in the p75^{NTR} killing pathway may be dependent on interactions either directly with the BH domains or with the hydrophobic cleft, as indicated with experiments using the W188A mutation. Co-expression of p75^{NTR} with the Bcl-2 W188A protein not only abrogated the increased p75^{NTR} killing but, more importantly, protected neurons from any p75^{NTR}-induced death, reminiscent of that seen with Bcl-xL. These experiments suggest that the conformation of the Bcl-2 protein is integral to the opposing functions observed herein.

10

The inventors had observed that DRG neurons isolated from newborn mice depleted for p75^{NTR} were less susceptible to NGF withdrawal, as is the case with sympathetic neurons, when compared to neurons from wildtype mice. This is indicative of absent or delayed naturally occurring cell death observed in these mice. The inventors attempted to induce cell death in p75^{NTR} "knock out" DRG neurons by re-introducing p75^{NTR} expression.

15

Surprisingly, apoptosis was not induced by re-expression into "knock out" DRG neurons, the inventors found that neuronal death was significantly increased under these conditions. This implicated an absolute requirement for Bcl-2 in mediating p75^{NTR} killing.

20 The inventors tested, therefore, whether high endogenous Bcl-2 levels might be necessary for successful p75^{NTR}-mediated killing in normal neurons by assaying p75^{NTR} killing in Bcl-2 depleted cells. Endogenous Bcl-2 was down regulated by antisense as previously described. When the Bcl-2 antisense plasmid was injected at the same time as p75^{NTR} plasmids no diminishment in the death signal was seen. If, however, the Bcl-2 antisense was

25 microinjected first (to give time to reduced Bcl-2 production and deplete endogenous Bcl-2; and then a day later the p75^{NTR} or p75^{NTR}nc constructs were microinjected, there was no difference in survival between p75^{NTR} and p75^{NTR}nc expressing neurons, strongly suggesting that endogenous Bcl-2 is required for p75^{NTR} killing effects. To confirm this observation, the inventors isolated neurons from newborn Bcl-2 "knock out" mice (an heterozygous line of

30 mice containing a disrupted Bcl-2 gene) and their wild-type litter mates and compared the effect of p75^{NTR} over-expression with control plasmid p75^{NTR}. It was found that the neurons

isolated from Bcl-2 deficient mice were significantly protected from p75^{NTR} killing, showing a 56.9% (n=3) reduction in death compared wildtype neurons, supporting the hypothesis that endogenous Bcl-2 is required for p75^{NTR} killing.

- 5 Bcl-2 has previously been observed to increase cell death when highly expressed both *in vitro* and *in vivo* when expressed at high levels as a transgene, causing increased apoptosis in the brain under a neuron specific promoter, or in photoreceptor cells when expressed specifically under a rhodopsin promoter. Thus, it is possible that the high level of Bcl-2 is able to "prime" the death pathway such that an apoptotic stimulus *via* p75^{NTR} results in rapid cell
- 10 death.

Bcl-2 and Bcl-xL when cleaved by caspases have also been shown to be capable of promoting apoptosis *in vitro*, with cells expressing non-cleavable mutant Bcl-2 and Bcl-xL proteins showing increased viability compared to cells expressing wildtype proteins.

- 15 Cleavage of Bcl-2 is possible in this system, however, the Bcl-2 mutations which results in loss of death promoting activity, would not prevent cleavage of Bcl-2, indicating that cleavage of Bcl-2 would only be part of the mechanism by which Bcl-2 promotes killing. In addition, if cleavage was the dominant mechanism, Bcl-xL might be expected to act as a death signalling protein in this system.

20

- To investigate whether the p75^{NTR}-Bcl-2 death-signalling cascade was dependent on caspase activation, inhibitors of caspases were employed. In the presence of z-VAD, a nonspecific caspase peptide inhibitor, or after co-expression of modified crmA plasmids, designed to inhibit Group II caspases such as caspases 2 and 3, p75^{NTR}-mediated death was significantly
- 25 reduced. Similarly, the modified crmA was able to block the killing induced by co-expression of p75^{NTR} and Bcl-2. This indicates that p75^{NTR} induced apoptosis is a caspase dependent pathway and that the mechanism by which Bcl-2 assists killing is through the same pathway.

EXAMPLE 4

ANTAGONISM OF p75^{NTR} MEDIATED DEATH SIGNALLING

Figure 6 shows that soluble c35 (35mer) [<400>7 and <400>8] protects cells from death
5 signalling in a dose-dependent manner against membrane bound c35. Furthermore, the
35mer when expressed from a genetic construct, protected Schwann cells against NGF-
induced death. c35 when expressed in soluble form can also protect cells against membrane
bound c35. The inventors show in Figure 7 that soluble c35 can also protect against
membrane-linked, expressed c35. A truncated form of c35, a 29mer [<400>11 and
10 <400>12], also protected against membrane-bound c35, when in soluble form.

Figure 8 shows that the 29mer with a palmitoyl group at the membrane (amino) end resulted
in cell death. The palmitoylation links the peptide to the plasma membrane. This membrane-
linked 29mer leads to cell death whereas its soluble form protects cells against p75^{NTR}-
15 mediated death signalling.

Those skilled in the art will appreciate that the invention described herein is susceptible to
variations and modifications other than those specifically described. It is to be understood
that the invention includes all such variations and modifications. The invention also includes
20 all of the steps, features, compositions and compounds referred to or indicated in this
specification, individually or collectively, and any and all combinations of any two or more of
said steps or features.

BIBLIOGRAPHY

1. Levi-Montalcini, 1982. *Ann. Rev. Neurosci.* 5: 341-362.
2. Rabizadeh, et al., *Science*, 1993. 261(5119): p. 345-8.
3. Majdan, et al., *Journal of Neuroscience*, 1997. 17(18): p. 6988-98.
4. Barrett, G.L. and A. Georgiou, *Journal of Neuroscience Research*, 1996. 45(2): p. 117-28.
5. Barrett, G.L. and P.F. Bartlett, *Proceedings of the National Academy of Sciences of the United States of America*, 1994. 91(14): p. 6501-5.
6. Cheema, S.S., G.L. Barrett, and P.F. Bartlett, *Journal of Neuroscience Research*, 1996. 46(2): p. 239-45.
7. Bamji, S.X., et al., *Journal of Cell Biology*, 1998. 140(4): p. 911-23.
8. Van der Zee, et al., *Science*, 1996. 274(5293): p. 1729-32.
9. Feinstein, et al., *Trends in Biochemical Sciences*, 1995. 20(9): p. 342-4.
10. Moix, et al., *Brain Research*, 1991. 564(1): p. 176-80.
11. Lee, et al., *Journal of Neuroscience Research*, 1995. 41(5): p. 684-95.
12. Rende, et al., *Journal of Comparative Neurology*, 1995. 363(2): p. 249-63.
13. Seeburger, et al., *Brain Research*, 1993. 621(1): p. 111-5.
14. De Simone, et al., *Neuropathology & Applied Neurobiology*, 1996. 22(1): p. 54-9.
15. Conner, et al., *Journal of Comparative Neurology*, 1992. 319(3): p. 454-62.
16. Wiley, et al., *Journal of the Neurological Sciences*, 1995. 128(2): p. 157-66.
17. Needleman and Wunsch, 1970. *J. Mol. Biol.* 48: 443-453.

- 42 -

SEQUENCE LISTING

<110> THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

<120> A METHOD OF MODULATING CELL SURVIVAL AND REAGENTS
USEFUL FOR SAME-III

<130> EJH/AF

<140>

<141>

<150> PP6353

<151> 1998-10-06

<150> PP6351

<151> 1998-10-07

<160> 12

<170> PatentIn Ver. 2.0

<210> 1

<211> 3260

<212> DNA

<213> Human

<220>

<223> Description of Artificial Sequence:Synthetic

<220>

<221> CDS

<222> (115)..(1389)

<400> 1

acagctccgg cgggcagcag gcgctggagc gcatcgagcag tcagctcagc gcagcaccat 60

cggtctgcgg agcggactga gctagaagcg gagcgctgac gccggaggcg tgca atg 117
Met
1agg agg gca ggt gct gcc tgc agc gcc atg gac cgg ctg cgc ctg ctg 165
Arg Arg Ala Gly Ala Ala Cys Ser Ala Met Asp Arg Leu Arg Leu Leu
5 10 15ctg ctg ctg att cta ggg gtg tcc tct gga ggt gcc aag gag aca tgt 213
Leu Leu Leu Ile Leu Gly Val Ser Ser Gly Gly Ala Lys Glu Thr Cys
20 25 30tcc aca ggc ctg tac acc cac agc gga gag tgc tgc aaa gcc tgc aac 261
Ser Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys Lys Ala Cys Asn
35 40 45

- 43 -

ttg ggc gaa ggc gtg gcc cag ccc tgc gga gcc aac cag acc gtg tgt	309
Leu Gly Glu Gly Val Ala Gln Pro Cys Gly Ala Asn Gln Thr Val Cys	
50 55 60 65	
gaa ccc tgc ctg gac aat gtt aca ttc tcc gat gtg gtg agc gcc act	357
Glu Pro Cys Leu Asp Asn Val Thr Phe Ser Asp Val Val Ser Ala Thr	
70 75 80	
gag ccg tgc aag ccg tgc acc gag tgc ctg ggc ctg cag agc atg tcc	405
Glu Pro Cys Lys Pro Cys Thr Glu Cys Leu Gly Leu Gln Ser Met Ser	
85 90 95	
gct ccc tgt gtg gag gca gac gat gca gtg tgc aga tgt gcc tat ggc	453
Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr Gly	
100 105 110	
tac tac cag gac gag gag act ggc cac tgt gag gct tgc agc gtg tgc	501
Tyr Tyr Gln Asp Glu Glu Thr Gly His Cys Glu Ala Cys Ser Val Cys	
115 120 125	
gag gtg ggc tgc gga ctc gtg ttc tcc tgc cag gac aaa cag aac aca	549
Glu Val Gly Ser Gly Leu Val Phe Ser Cys Gln Asp Lys Gln Asn Thr	
130 135 140 145	
gtg tgt gaa gag tgc cca gag ggc aca tac tca gac gaa gcc aac cac	597
Val Cys Glu Glu Cys Pro Glu Gly Thr Tyr Ser Asp Glu Ala Asn His	
150 155 160	
gtg gac ccg tgc cta ccc tgc acg gtg tgc gag gac act gag cgc cag	645
Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp Thr Glu Arg Gln	
165 170 175	
tta cgc gag tgc acg ccc tgg gct gat gct gaa tgc gaa gag atc cct	693
Leu Arg Glu Cys Thr Pro Trp Ala Asp Ala Glu Cys Glu Glu Ile Pro	
180 185 190	
ggt cga tgg atc cca agg tct acg ccc ccg gag ggc tcc gac agc aca	741
Gly Arg Trp Ile Pro Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser Thr	
195 200 205	
gcg ccc agc acc cag gag cct gag gtt cct cca gag caa gac ctt gta	789
Ala Pro Ser Thr Gln Glu Pro Glu Val Pro Pro Glu Gln Asp Leu Val	
210 215 220 225	
ccc agt aca gtg gcg gat atg gtg acc act gtg atg ggc agc tcc cag	837
Pro Ser Thr Val Ala Asp Met Val Thr Thr Val Met Gly Ser Ser Gln	
230 235 240	
cct gta gtg acc cgc ggc acc acc gac aac ctc att cct gtc tat tgc	885
Pro Val Val Thr Arg Gly Thr Thr Asp Asn Leu Ile Pro Val Tyr Cys	
245 250 255	

- 44 -

tcc atc ttg gct gct gtg gtc gtg ggc ctt gtg gcc tat att gct ttc	933
Ser Ile Leu Ala Ala Val Val Val Gly Leu Val Ala Tyr Ile Ala Phe	
260 265 270	
aag agg tgg aac agc tgc aaa caa aat aaa caa ggc gcc aac agc cgc	981
Lys Arg Trp Asn Ser Cys Lys Gln Asn Lys Gln Gly Ala Asn Ser Arg	
275 280 285	
ccc gtg aac cag acg ccc cca ccg gag gga gag aaa ctg cac agc gac	1029
Pro Val Asn Gln Thr Pro Pro Pro Glu Gly Glu Lys Leu His Ser Asp	
290 295 300 305	
agt ggc atc tct gtg gac agc cag agc ctg cac gac cag cag acc cat	1077
Ser Gly Ile Ser Val Asp Ser Gln Ser Leu His Asp Gln Gln Thr His	
310 315 320	
acg cag act gcc tca ggc cag gcc ctc aag ggt gat ggc aac ctc tac	1125
Thr Gln Thr Ala Ser Gly Gln Ala Leu Lys Gly Asp Gly Asn Leu Tyr	
325 330 335	
agt agc ctg ccc ctg acc aag cgt gag gag gta gag aaa ctg ctc aac	1173
Ser Ser Leu Pro Leu Thr Lys Arg Glu Glu Val Glu Lys Leu Leu Asn	
340 345 350	
ggg gat acc tgg cga cat ctg gca ggc gag ctg ggt tac cag cct gaa	1221
Gly Asp Thr Trp Arg His Leu Ala Gly Glu Leu Gly Tyr Gln Pro Glu	
355 360 365	
cat ata gac tcc ttt acc cac gag gcc tgc cca gtg cga gcc ctg ctg	1269
His Ile Asp Ser Phe Thr His Glu Ala Cys Pro Val Arg Ala Leu Leu	
370 375 380 385	
gcc agc tgg ggt gcc cag gac agt gca acg ctt gat gcc ctt tta gcc	1317
Ala Ser Trp Gly Ala Gln Asp Ser Ala Thr Leu Asp Ala Leu Leu Ala	
390 395 400	
gcc ctg cga cgc atc cag aga gct gac att gtg gag agt cta tgc agc	1365
Ala Leu Arg Arg Ile Gln Arg Ala Asp Ile Val Glu Ser Leu Cys Ser	
405 410 415	
gag tcc act gcc aca tcc cca gtg tgaactcaca gactgggagc ccctgtcctg	1419
Glu Ser Thr Ala Thr Ser Pro Val	
420 425	
tcccacattc cgacgactga tgttctagcc agccccaca gagctgcccc ctctccctcg	1479
gggatggccc aacggtcaga acggagcatc tctgtgcagg gcctctgtgt tcccactcct	1539
gactccgttg ctgctcccga gggggccctt gcttctgacc accctctcct cagcaagaga	1599

- 45 -

gagagagagg accacccgag cctgacttgc tccatttcca tctcaggcct ttccttcctt 1659
tctacacatt agctgtgtca gatctggggg tttgacacta ggagaaggga gcggggggcac 1719
ccctaagact caggaggtag tgaagaacca gagccatgga ctccacactg tgaaccggag 1779
aacaaggggc ggggcattgt ggtaggctag accttcctta gccctccct tctccctct 1839
ggccaaagaa gaggattacg gacctatctg agctgaaagc aggtttggaa cccagcccac 1899
acttctctct cacacacagg atggtaaaac ccagagaaag gcagggactg acctaggcca 1959
cccaaccaca ggaagaacaa atgaaggctg atacactccg tttctgaatg agggcgctcaa 2019
gtgtgcttgt tgacagggat ggcgtgactt tcagggaat atctggaagc catgtctgcc 2079
ccgccctcaa ccacttccag gccctaccc aaccttgtg cagatgaact gtttgttcaa 2139
gggctgggtcc attggtctat tctgatggag tcaagctaag ggctcaggct tatccataag 2199
gcatttgtgg agagatgaat ctgttagtgc gctcattctt ggcataagcc tgaagccaac 2259
acggccctta atgtcagccc tcggggtcag gaaccaagga ctcccacccc acaatccaac 2319
actatactac attacacaca cacacacaca cacacacaca cacacacaca cacacacaca 2379
gatattcttgc ttttctcccc atggctcttt tggggctgag actagatcct gctgggagtc 2439
actgccagtg agagatccgg aggggacaga gctgagcttc atggggctgt ctctctcgcc 2499
cccgggtctg gcaggccaag aatgactgca tctgagctgg tgtctgtctt ccaatggcct 2559
gtgctgggag gaaatgctcc cactcctccc cttcttgaag ctgccccag aagactacag 2619
tgcaaaagag cagactggtg tgagaacaca agaaaaagca gatgctggcc ctgcagtctg 2679
tggcagcttt ctctcagct tcaaggcccc tgcaaaggac ggatttctg agcacggcca 2739
ggaaggggca agagggttcg gttcagtggc gctttctccc ggctccttgg cctgttctgt 2799
tttgcttgct gttggaatga gtgggcaccc cctctattta gcatgaagga gccccaggca 2859
gggtatgcac agactgacca ccatccctcc ccacccaggg tccaccaaac ccggtgaaga 2919
gaccaggagc attgtacgca tacgcggtg gtatttttat ggacccaat ctgcaattcc 2979
cagacacctg ggaagtggga cattctttgt gtattttatt tcctccccag gagctgggga 3039
gtggtggggg gctgcaggta cggtttagca tgtgtttggt tctgggggtc tctccagcct 3099
tgttttgggc caagttggaa cctctggccc tccagctggt gactatgaac tccagacccc 3159

- 46 -

ttcgtgctcc ccgacgcctt cccttgcat cctgtgtaac catttcgttg ggccctccca 3219

aaacctacac ataaaacata caggaggacc attaaattgg c 3260

<210> 2

<211> 425

<212> PRT

<213> Human

<400> 2

Met Arg Arg Ala Gly Ala Ala Cys Ser Ala Met Asp Arg Leu Arg Leu
1 5 10 15

Leu Leu Leu Leu Ile Leu Gly Val Ser Ser Gly Gly Ala Lys Glu Thr
20 25 30

Cys Ser Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys Lys Ala Cys
35 40 45

Asn Leu Gly Glu Gly Val Ala Gln Pro Cys Gly Ala Asn Gln Thr Val
50 55 60

Cys Glu Pro Cys Leu Asp Asn Val Thr Phe Ser Asp Val Val Ser Ala
65 70 75 80

Thr Glu Pro Cys Lys Pro Cys Thr Glu Cys Leu Gly Leu Gln Ser Met
85 90 95

Ser Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr
100 105 110

Gly Tyr Tyr Gln Asp Glu Glu Thr Gly His Cys Glu Ala Cys Ser Val
115 120 125

Cys Glu Val Gly Ser Gly Leu Val Phe Ser Cys Gln Asp Lys Gln Asn
130 135 140

Thr Val Cys Glu Glu Cys Pro Glu Gly Thr Tyr Ser Asp Glu Ala Asn
145 150 155 160

His Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp Thr Glu Arg
165 170 175

Gln Leu Arg Glu Cys Thr Pro Trp Ala Asp Ala Glu Cys Glu Glu Ile
180 185 190

Pro Gly Arg Trp Ile Pro Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser
195 200 205

Thr Ala Pro Ser Thr Gln Glu Pro Glu Val Pro Pro Glu Gln Asp Leu

- 47 -

210				215				220							
Val	Pro	Ser	Thr	Val	Ala	Asp	Met	Val	Thr	Thr	Val	Met	Gly	Ser	Ser
225					230					235					240
Gln	Pro	Val	Val	Thr	Arg	Gly	Thr	Thr	Asp	Asn	Leu	Ile	Pro	Val	Tyr
				245					250					255	
Cys	Ser	Ile	Leu	Ala	Ala	Val	Val	Val	Gly	Leu	Val	Ala	Tyr	Ile	Ala
			260						265				270		
Phe	Lys	Arg	Trp	Asn	Ser	Cys	Lys	Gln	Asn	Lys	Gln	Gly	Ala	Asn	Ser
		275					280						285		
Arg	Pro	Val	Asn	Gln	Thr	Pro	Pro	Pro	Glu	Gly	Glu	Lys	Leu	His	Ser
	290					295					300				
Asp	Ser	Gly	Ile	Ser	Val	Asp	Ser	Gln	Ser	Leu	His	Asp	Gln	Gln	Thr
305					310					315					320
His	Thr	Gln	Thr	Ala	Ser	Gly	Gln	Ala	Leu	Lys	Gly	Asp	Gly	Asn	Leu
				325					330					335	
Tyr	Ser	Ser	Leu	Pro	Leu	Thr	Lys	Arg	Glu	Glu	Val	Glu	Lys	Leu	Leu
			340						345				350		
Asn	Gly	Asp	Thr	Trp	Arg	His	Leu	Ala	Gly	Glu	Leu	Gly	Tyr	Gln	Pro
		355					360						365		
Glu	His	Ile	Asp	Ser	Phe	Thr	His	Glu	Ala	Cys	Pro	Val	Arg	Ala	Leu
	370					375				380					
Leu	Ala	Ser	Trp	Gly	Ala	Gln	Asp	Ser	Ala	Thr	Leu	Asp	Ala	Leu	Leu
385					390					395					400
Ala	Ala	Leu	Arg	Arg	Ile	Gln	Arg	Ala	Asp	Ile	Val	Glu	Ser	Leu	Cys
			405						410					415	
Ser	Glu	Ser	Thr	Ala	Thr	Ser	Pro	Val							
			420				425								

<210> 3
 <211> 867
 <212> DNA
 <213> Rat

<220>
 <223> Description of Artificial Sequence:Synthetic

<220>
 <221> CDS

- 48 -

<222> (115)..(867)

<400> 3

```

acagctccgg cgggcagcag gcgctggagc gcatcgagc tcagctcage gcagcacat 60

cggtctgcgg agcggactga gctagaagcg gagcgctgac gccggaggcg tgca atg 117
                                         Met
                                         1

agg agg gca ggt gct gcc tgc agc gcc atg gac cgg ctg cgc ctg ctg 165
Arg Arg Ala Gly Ala Ala Cys Ser Ala Met Asp Arg Leu Arg Leu Leu
          5                      10                      15

ctg ctg ctg att cta ggg gtg tcc tct gga ggt gcc aag gag aca tgt 213
Leu Leu Leu Ile Leu Gly Val Ser Ser Gly Gly Ala Lys Glu Thr Cys
          20                      25                      30

tcc aca ggc ctg tac acc cac agc gga gag tgc tgc aaa gcc tgc aac 261
Ser Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys Lys Ala Cys Asn
          35                      40                      45

ttg ggc gaa ggc gtg gcc cag ccc tgc gga gcc aac cag acc gtg tgt 309
Leu Gly Glu Gly Val Ala Gln Pro Cys Gly Ala Asn Gln Thr Val Cys
          50                      55                      60                      65

gaa ccc tgc ctg gac aat gtt aca ttc tcc gat gtg gtg agc gcc act 357
Glu Pro Cys Leu Asp Asn Val Thr Phe Ser Asp Val Val Ser Ala Thr
          70                      75                      80

gag ccg tgc aag ccg tgc acc gag tgc ctg ggc ctg cag agc atg tcc 405
Glu Pro Cys Lys Pro Cys Thr Glu Cys Leu Gly Leu Gln Ser Met Ser
          85                      90                      95

gct ccc tgt gtg gag gca gac gat gca gtg tgc aga tgt gcc tat ggc 453
Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr Gly
          100                      105                      110

tac tac cag gac gag gag act ggc cac tgt gag gct tgc agc gtg tgc 501
Tyr Tyr Gln Asp Glu Glu Thr Gly His Cys Glu Ala Cys Ser Val Cys
          115                      120                      125

gag gtg ggc tcg gga ctc gtg ttc tcc tgc cag gac aaa cag aac aca 549
Glu Val Gly Ser Gly Leu Val Phe Ser Cys Gln Asp Lys Gln Asn Thr
          130                      135                      140                      145

gtg tgt gaa gag tgc cca gag ggc aca tac tca gac gaa gcc aac cac 597
Val Cys Glu Glu Cys Pro Glu Gly Thr Tyr Ser Asp Glu Ala Asn His
          150                      155                      160

gtg gac ccg tgc cta ccc tgc acg gtg tgc gag gac act gag cgc cag 645
Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp Thr Glu Arg Gln

```

- 49 -

165	170	175	
tta cgc gag tgc acg ccc tgg gct gat gct gaa tgc gaa gag atc cct			693
Leu Arg Glu Cys Thr Pro Trp Ala Asp Ala Glu Cys Glu Glu Ile Pro			
180	185	190	
ggt cga tgg atc cca agg tct acg ccc ccg gag ggc tcc gac agc aca			741
Gly Arg Trp Ile Pro Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser Thr			
195	200	205	
gcg ccc agc acc cag gag cct gag gtt cct cca gag caa gac ctt gta			789
Ala Pro Ser Thr Gln Glu Pro Glu Val Pro Pro Glu Gln Asp Leu Val			
210	215	220	225
ccc agt aca gtg gcg gat atg gtg acc act gtg atg ggc agc tcc cag			837
Pro Ser Thr Val Ala Asp Met Val Thr Thr Val Met Gly Ser Ser Gln			
230	235	240	
cct gta gtg acc cgc ggc acc acc gac aac			867
Pro Val Val Thr Arg Gly Thr Thr Asp Asn			
245	250		
<210> 4			
<211> 251			
<212> PRT			
<213> Rat			
<400> 4			
Met Arg Arg Ala Gly Ala Ala Cys Ser Ala Met Asp Arg Leu Arg Leu			
1	5	10	15
Leu Leu Leu Leu Ile Leu Gly Val Ser Ser Gly Gly Ala Lys Glu Thr			
20	25	30	
Cys Ser Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys Lys Ala Cys			
35	40	45	
Asn Leu Gly Glu Gly Val Ala Gln Pro Cys Gly Ala Asn Gln Thr Val			
50	55	60	
Cys Glu Pro Cys Leu Asp Asn Val Thr Phe Ser Asp Val Val Ser Ala			
65	70	75	80
Thr Glu Pro Cys Lys Pro Cys Thr Glu Cys Leu Gly Leu Gln Ser Met			
85	90	95	
Ser Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr			
100	105	110	
Gly Tyr Tyr Gln Asp Glu Glu Thr Gly His Cys Glu Ala Cys Ser Val			
115	120	125	

- 50 -

Cys Glu Val Gly Ser Gly Leu Val Phe Ser Cys Gln Asp Lys Gln Asn
 130 135 140

Thr Val Cys Glu Glu Cys Pro Glu Gly Thr Tyr Ser Asp Glu Ala Asn
 145 150 155 160

His Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp Thr Glu Arg
 165 170 175

Gln Leu Arg Glu Cys Thr Pro Trp Ala Asp Ala Glu Cys Glu Glu Ile
 180 185 190

Pro Gly Arg Trp Ile Pro Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser
 195 200 205

Thr Ala Pro Ser Thr Gln Glu Pro Glu Val Pro Pro Glu Gln Asp Leu
 210 215 220

Val Pro Ser Thr Val Ala Asp Met Val Thr Thr Val Met Gly Ser Ser
 225 230 235 240

Gln Pro Val Val Thr Arg Gly Thr Thr Asp Asn
 245 250

<210> 5

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(66)

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 5

ctc att cct gtc tat tgc tcc atc ttg gct gct gtg gtc gtg ggc ctt 48
 Leu Ile Pro Val Tyr Cys Ser Ile Leu Ala Ala Val Val Val Gly Leu
 1 5 10 15

gtg gcc tat att gct ttc 66
 Val Ala Tyr Ile Ala Phe
 20

<210> 6

<211> 22

<212> PRT

- 51 -

<213> Artificial Sequence

<400> 6

Leu Ile Pro Val Tyr Cys Ser Ile Leu Ala Ala Val Val Val Gly Leu
 1 5 10 15

Val Ala Tyr Ile Ala Phe
 20

<210> 7

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(105)

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 7

aag agg tgg aac agc tgc aaa caa aat aaa caa ggc gcc aac agc cgc 48
 Lys Arg Trp Asn Ser Cys Lys Gln Asn Lys Gln Gly Ala Asn Ser Arg
 1 5 10 15

ccc gtg aac cag acg ccc cca ccg gag gga gag aaa ctg cac agc gac 96
 Pro Val Asn Gln Thr Pro Pro Pro Glu Gly Glu Lys Leu His Ser Asp
 20 25 30

agt ggc atc 105
 Ser Gly Ile
 35

<210> 8

<211> 35

<212> PRT

<213> Artificial Sequence

<400> 8

Lys Arg Trp Asn Ser Cys Lys Gln Asn Lys Gln Gly Ala Asn Ser Arg
 1 5 10 15

Pro Val Asn Gln Thr Pro Pro Pro Glu Gly Glu Lys Leu His Ser Asp
 20 25 30

Ser Gly Ile
 35

- 52 -

<210> 9

<211> 2222

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<220>

<221> CDS

<222> (1)..(351)

<400> 9

tct	gtg	gac	agc	cag	agc	ctg	cac	gac	cag	cag	acc	cat	acg	cag	act	48
Ser	Val	Asp	Ser	Gln	Ser	Leu	His	Asp	Gln	Gln	Thr	His	Thr	Gln	Thr	
1				5					10					15		

gcc	tca	ggc	cag	gcc	ctc	aag	ggt	gat	ggc	aac	ctc	tac	agt	agc	ctg	96
Ala	Ser	Gly	Gln	Ala	Leu	Lys	Gly	Asp	Gly	Asn	Leu	Tyr	Ser	Ser	Leu	
			20					25					30			

ccc	ctg	acc	aag	cgt	gag	gag	gta	gag	aaa	ctg	ctc	aac	ggg	gat	acc	144
Pro	Leu	Thr	Lys	Arg	Glu	Glu	Val	Glu	Lys	Leu	Leu	Asn	Gly	Asp	Thr	
		35					40					45				

tgg	cga	cat	ctg	gca	ggc	gag	ctg	ggt	tac	cag	cct	gaa	cat	ata	gac	192
Trp	Arg	His	Leu	Ala	Gly	Glu	Leu	Gly	Tyr	Gln	Pro	Glu	His	Ile	Asp	
	50					55				60						

tcc	ttt	acc	cac	gag	gcc	tgc	cca	gtg	cga	gcc	ctg	ctg	gcc	agc	tgg	240
Ser	Phe	Thr	His	Glu	Ala	Cys	Pro	Val	Arg	Ala	Leu	Leu	Ala	Ser	Trp	
65					70				75					80		

ggt	gcc	cag	gac	agt	gca	acg	ctt	gat	gcc	ctt	tta	gcc	gcc	ctg	cga	288
Gly	Ala	Gln	Asp	Ser	Ala	Thr	Leu	Asp	Ala	Leu	Leu	Ala	Ala	Leu	Arg	
			85					90					95			

cgc	atc	cag	aga	gct	gac	att	gtg	gag	agt	cta	tgc	agc	gag	tcc	act	336
Arg	Ile	Gln	Arg	Ala	Asp	Ile	Val	Glu	Ser	Leu	Cys	Ser	Glu	Ser	Thr	
		100					105					110				

gcc	aca	tcc	cca	gtg	tgaactcaca	gactgggagc	ccctgtcctg	tcccacattc	391
Ala	Thr	Ser	Pro	Val					
					115				

cgacgactga	tgttctagcc	agccccacaca	gagctgcccc	ctctccctcg	gggatggccc	451
------------	------------	-------------	------------	------------	------------	-----

aacggtcaga	acggagcatc	tctgtgcagg	gcctctgtgt	tccactcct	gactccgttg	511
------------	------------	------------	------------	-----------	------------	-----

ctgctcccga	gggggccctt	gcttctgacc	accctctcct	cagcaagaga	gagagagagg	571
------------	------------	------------	------------	------------	------------	-----



- 53 -

accacccgag cctgacttgc tccatttcca tctcaggcct ttccttcctt tctacacatt 631
agctgtgtca gatctggggg tttgacacta ggagaaggga gcggggggcac ccctaagact 691
caggaggtac tgaagaacca gagccatgga ctccacactg tgaaccggag aacaaggggc 751
ggggcattgt ggtaggctag accttcctta gcccctccct tctccccctt ggccaaagaa 811
gaggattacg gacctatctg agctgaaagc aggtttggaa cccagcccac acttctctct 871
cacacacagg atggtaaaac ccagagaaag gcagggactg acctaggcca cccaaccaca 931
ggaagaacaa atgaaggctg atacactccg tttctgaatg agggcgtaa gtgtgcttgt 991
tgacagggat ggcgtgactt tcagggaaat atctggaagc catgtctgcc ccgccctcaa 1051
ccacttccag gccctaccc aacccttggtg cagatgaact gtttgttcaa gggctgggtcc 1111
attggtctat tctgatggag tcaagctaag ggctcaggct tatccataag gcatttgtgg 1171
agagatgaat ctgttagtgc gctcattctt ggcataagcc tgaagccaac acggccctta 1231
atgtcagccc tcggggtcag gaaccaagga ctcccacccc acaatccaac actatactac 1291
attacacaca cacacacaca cacacacaca cacacacaca cacacacaca gatatcttgc 1351
ttttctcccc atggctcttt tggggctgag actagatcct gctgggagtc actgccagt 1411
agagatccgg aggggacaga gctgagcttc atggggctgt ctctctcgcc cccgggtctg 1471
gcaggccaag aatgactgca tctgagctgg tgtctgtctt ccaatggcct gtgcgtggag 1531
gaaatgctcc cactcctccc cttcttgaag ctgccccag aagactacag tgcaaaagag 1591
cagactgggtg tgagaacaca agaaaaagca gatgctggcc ctgcagtctg tggcagcttt 1651
ctctcagct tcaaggcccc tgcaaaggac ggatttcctg agcacggcca ggaaggggca 1711
agagggttcg gttcagtggc gctttctccc ggctccttgg cctgttctgt tttgcttgct 1771
gttggaatga gtgggcaccc cctctattta gcatgaagga gcccaggca gggatatgcac 1831
agactgacca ccatccctcc ccacccaggg tccaccaaac ccggtgaaga gaccaggagc 1891
attgtacgca tacgcggtg gtatttttat ggacccaat ctgcaattcc cagacacctg 1951
ggaagtggga cattctttgt gtattttatt tcctccccag gagctgggga gtgggtgggg 2011
gctgcaggta cggtttagca tgtgtttggt tctgggggtc tctccagcct tgttttgggc 2071
caagttggaa cctctggccc tccagctggt gactatgaac tccagacccc ttcgtgctcc 2131

- 54 -

ccgacgcctt ccccttgcat cctgtgtaac catttcgttg ggccctccca aaacctacac 2191
 ataaaacata caggaggacc attaaattgg c 2222

<210> 10
 <211> 117
 <212> PRT
 <213> Artificial Sequence

<400> 10
 Ser Val Asp Ser Gln Ser Leu His Asp Gln Gln Thr His Thr Gln Thr
 1 5 10 15
 Ala Ser Gly Gln Ala Leu Lys Gly Asp Gly Asn Leu Tyr Ser Ser Leu
 20 25 30
 Pro Leu Thr Lys Arg Glu Glu Val Glu Lys Leu Leu Asn Gly Asp Thr
 35 40 45
 Trp Arg His Leu Ala Gly Glu Leu Gly Tyr Gln Pro Glu His Ile Asp
 50 55 60
 Ser Phe Thr His Glu Ala Cys Pro Val Arg Ala Leu Leu Ala Ser Trp
 65 70 75 80
 Gly Ala Gln Asp Ser Ala Thr Leu Asp Ala Leu Leu Ala Ala Leu Arg
 85 90 95
 Arg Ile Gln Arg Ala Asp Ile Val Glu Ser Leu Cys Ser Glu Ser Thr
 100 105 110
 Ala Thr Ser Pro Val
 115

<210> 11
 <211> 87
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(87)

<220>
 <223> Description of Artificial Sequence:Synthetic

<400> 11
 aag agg tgg aac agc tgc aaa caa aat aaa caa ggc gcc aac agc cgc 48
 Lys Arg Trp Asn Ser Cys Lys Gln Asn Lys Gln Gly Ala Asn Ser Arg

- 55 -

1	5	10	15	
ccc gtg aac cag acg ccc cca ccg gag gga gag aaa ctg				
Pro Val Asn Gln Thr Pro Pro Pro Glu Gly Glu Lys Leu				
	20	25		87

<210> 12
 <211> 29
 <212> PRT
 <213> Artificial Sequence

<400> 12															
Lys	Arg	Trp	Asn	Ser	Cys	Lys	Gln	Asn	Lys	Gln	Gly	Ala	Asn	Ser	Arg
1				5					10					15	
Pro Val Asn Gln Thr Pro Pro Pro Glu Gly Glu Lys Leu															
			20						25						

DATED this 1st day of June, 1999

THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

By Its Patent Attorneys

DAVIES COLLISON CAVE

FIGURE 1





FIGURE 2

Survival of DRG neurons 17 hrs after microinjection, cultured in LIF




p75nc.
78.3 ± 0.4

p75
64.4 ± 7

p75TM.
57.9 ± 0.6

FIGURE 3

DRG survival 16hr after microinjection,
cultured in LIF



GFP = the vector utilised

FIGURE 4

**C57 DRG survival 20 hr after microinjection,
cultured in LIF**






FIGURE 5



Soluble c35 can inhibit p75NTR-mediated death




sptc35:c35

FIGURE 6

s.e.m.

Protection of membrane-bound killing-domain by soluble peptide



treatment: microinjection of sptc35/GFP followed by 30' peptide treatment.
all conditions contain penetratin

S.D.

FIGURE 7




FIGURE 8